Medical consequences of stopping anticoagulant therapy before intraocular surgery or intravitreal injections.
Charles
Steve
S
Rosenfeld
Philip J
PJ
Gayer
Steven
S
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000925:Anticoagulants / Q000008:administration & dosage*; D000068258:Bevacizumab; D005130:Eye Hemorrhage / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D007267:Injections; D013508:Ophthalmologic Surgical Procedures; D000069579:Ranibizumab; D012307:Risk Factors; D020521:Stroke / Q000209:etiology / Q000401:mortality; D013923:Thromboembolism / Q000209:etiology / Q000401:mortality; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014821:Vitrectomy; D014822:Vitreous Body; D014859:Warfarin / Q000008:administration & dosage*; D028761:Withholding Treatment
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000925:Anticoagulants; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D014859:Warfarin; D000069579:Ranibizumab